IP Library Granted Patent US 10,696,727
Granted Patent B2
US 10,696,727 · App. 14/584,895 · Granted Jun 30, 2020

Targeted delivery of glycine receptors to excitable cells

Inventors: Michael Cascio (Pittsburgh, PA); Joseph C. Glorioso, III (Blawnox, PA); James R. Goss (Bethel Park, PA); David Krisky (Sewickley, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
C07K14/705A01K67/0278A61K48/005C12N7/00C12N15/86A01K2217/20A01K2217/206A01K2227/105A01K2267/0356A01K2267/0393A61K38/00C12N2710/16643C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,727
App. No.
14/584,895
Granted
Jun 30, 2020
Kind
B2
Abstract

The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophy-stological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.

Claims (6)

1. A replication-defective HSV vector comprising an expression cassette encoding (i) a glycine receptor (GlyR) protein consisting of an alpha 1 subunit of GlyR and (ii) an expression control sequence that promotes the expression of the GlyR protein in peripheral neurons, wherein the HSV vector provides for the attenuation of pain sensation in a subject when administered to such peripheral neurons.

2. A viral stock comprising the vector of claim 1 having a titer of between about 10 6 plaque-forming units (pfu) and about 10 11 pfu.

3. A pharmaceutical composition comprising the vector of claim 1 and a pharmaceutically-acceptable carrier.

4. The pharmaceutical composition of claim 1 , formulated for injection.

5. The vector of claim 1 , wherein at least one of the peripheral neurons is a c-fiber.

6. The vector of claim 1 , wherein the subject is human.

Continuity (4)
Division 13043195 · Mar 8, 2011
Division 12152310 · May 14, 2008
Provisional Application 60917752 · May 14, 2007
Related Publication 20170081384A1 · Mar 23, 2017
Cited By (1)
US 12,208,126